ReviewFrontiers in allergy2026
Innovative diagnostic techniques and their clinical implications in food allergy: current clinical practice and future perspectives.
Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Food allergy (FA) is an immune-mediated adverse reaction to food components (mainly proteins) and represents an increasing global health problem, affecting millions of individuals and imposing substantial clinical, psychosocial, and economic burdens. Accurate diagnosis is essential to prevent life-threatening reactions while avoiding unnecessary dietary restrictions and impaired quality of life. Current diagnostic approaches rely on clinical history, skin prick tests (SPT), measurement of serum allergen-specific IgE (sIgE), and oral food challenges (OFC). However, SPT and sIgE are highly sensitive but lack specificity, frequently identifying clinically irrelevant sensitization, whereas OFC remains the diagnostic gold standard despite being resource-demanding and carrying a substantial risk of systemic reactions. In recent years, several innovative diagnostic approaches have emerged with the aim of improving diagnostic accuracy and reducing reliance on OFC. Component-resolved diagnostics (CRD) enable detailed characterization of molecular sensitization profiles, supporting improved risk stratification and identification of clinically relevant cross-reactivity patterns. Functional cellular assays, including the basophil activation test (BAT) and the mast cell activation test (MAT), offer direct assessment of IgE-mediated effector cell responses and have demonstrated higher diagnostic specificity compared with conventional testing. Epitope-specific IgE profiling and the allergen-specific IgG4/IgE ratio may additionally contribute to a better understanding of disease phenotype and evolution. Furthermore, advances in multi-omics technologies combined with artificial intelligence and machine learning are creating new opportunities for biomarker discovery and predictive modelling in FA. This narrative review summarizes current innovative diagnostic techniques in food allergy, discussing their clinical applications, limitations, and future directions toward more precise and personalized diagnostic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.